In support of this observation, Th1 cytokine IFN-γ in combination with MK-2206 treatment displayed similar tumor inhibitory effects in HER2/neu+ BC preclinical model and various HER2+ human BC cells (170). Here, ERBB2 is linked to breast cancer.